VIE

Uplizna® (inebilizumab-cdon)

Neuromyelitis Optica Spectrum Disorder

Stage (next event)

Expected Date

Quarterly Sales (Approved)

March 26, 2021 (Est)

Catalyst Info & Data Links

TITLE: Uplizna® (inebilizumab-cdon) in Neuromyelitis Optica Spectrum Disorder


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales (Approved)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • March 26, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE

Mechanism of Action

MECHANISM OF ACTION

  • The precise mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD is unknown but is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, inebilizumab-cdon results in antibody-dependent cellular cytolysis.

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

AMRN Litigation Update - 5/19/20 BIO Brief

ITCI - Investors Should Proceed with Caution with Imminent Phase 3 Readouts & FDA Decision In Co

FDA Decision on Heron's Non-Opioid Pain Med Imminent

Amp Core Q2 '19 Report

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon